Florence Salmon, PhD Novartis

Florence holds a PhD in Molecular and Cellular Biology from the Université Louis Pasteur in Strasbourg (France).

She gathered industry experience at BASF AG (Ludwigshafen, Germany) in the area of Product Safety and moved to TNO (Leiden/Zeist, the Netherlands) where she built up and led a DMPK and PK modelling research group for 12 years.

She gained considerable experience in development and regulatory affairs, bringing many of the early cell and gene therapies from the bench to the clinic.

Florence joined uniQure (Amsterdam, Netherlands) in 2009, where she was instrumental in the submission of the MAA and the approval of Glybera (first gene therapy approved in the Western world in 2012).

During her time at uniQure, she also supported the development of a number of AAV-based gene therapy vectors directed at various disease areas.

She joined Novartis in September 2014 as Director Regulatory Affairs CMC Cell and Gene Therapies, and is an active member of the Kymriah team.